CAJ | 학술논문

目的：探讨雄激素替代治疗( TRT)对男性迟发性性腺功能减退症( LOH)合并轻中度前列腺增生( BPH)的有效性和安全性。方法纳入LOH伴轻中度前列腺增生患者43例,分为治疗组和观察组。治疗组28例,口服十一酸睾酮(每次40 mg,每日2次,餐后服用),观察组15例,不做任何治疗。连续随访12个月,统计直肠指检结果、前列腺大小、IPSS 评分,最大尿流率( Qmax)、AMS临床症状评分、血清睾酮水平、血清PSA水平、红细胞比容( HCT)等指标变化情况。结果在治疗12个月后,对照组与治疗组前列腺体积均未见显著变化(P>0.05),治疗组IPSS评分、最大尿流率较治疗前有明显改善(P<0.05)；对照组IPSS评分、最大尿流率前后无明显差异(P>0.05)；治疗组与对照组之间AMS临床症状评分和血睾酮值在治疗前无显著差异(P>0.05),治疗12个月后治疗组患者睾酮水平基本达正常范围,AMS临床症状评分明显下降(P<0.05),对照组的相应指标在治疗前后并无显著差异(P>0.05)。结论 TRT对于伴有轻中度前列腺增生的LOH患者安全有效。
목적：탐토웅격소체대치료( TRT)대남성지발성성선공능감퇴증( LOH)합병경중도전렬선증생( BPH)적유효성화안전성。방법납입LOH반경중도전렬선증생환자43례,분위치료조화관찰조。치료조28례,구복십일산고동(매차40 mg,매일2차,찬후복용),관찰조15례,불주임하치료。련속수방12개월,통계직장지검결과、전렬선대소、IPSS 평분,최대뇨류솔( Qmax)、AMS림상증상평분、혈청고동수평、혈청PSA수평、홍세포비용( HCT)등지표변화정황。결과재치료12개월후,대조조여치료조전렬선체적균미견현저변화(P>0.05),치료조IPSS평분、최대뇨류솔교치료전유명현개선(P<0.05)；대조조IPSS평분、최대뇨류솔전후무명현차이(P>0.05)；치료조여대조조지간AMS림상증상평분화혈고동치재치료전무현저차이(P>0.05),치료12개월후치료조환자고동수평기본체정상범위,AMS림상증상평분명현하강(P<0.05),대조조적상응지표재치료전후병무현저차이(P>0.05)。결론 TRT대우반유경중도전렬선증생적LOH환자안전유효。
Objective To explore the safety and efficacy of testosterone replacement therapy in patients with male late-onset hypogon-adism and Mild-to-moderate benige prostate hyperplasia. Methods Forty-three patients diagnosed as male late-onset hypogonadism and Mild-to-moderate benige prostate hyperplasia were selected,of which 28 patients were assigned to Eleven acid testosterone (40 mg each time, after a meal,2 times per day) ,other patients were in the control group. The patients were followed for 12 months and their data about digital rectal inspection,size of the prostate,IPSS score,maximum urinary flow rate ( Qmax) ,AMS clinical symptom score,serum testosterone level, serum PSA level,RBC hematocrit ( HCT) ,and other indicators were collected. Results Twelve months After testosterone replacement thera-py,both the prostate volume of treated and control groups were not significantly changed(P>0. 05). IPSS score and maximum urinary flow rate in treatment group were improved significantly(P<0. 05),but the control group showed no statistically significant changes(P>0. 05). Baseline AMS clinical symptom score and blood testosterone level were similar between treatment and control group (P >0. 05). Twelve months after treatment,the blood testosterone level of the treatment group reached the normal range,and the AMS clinical symptom scores de-creased significantly (P<0. 05). However,none indexes of control group significantly changed after the treatment (P>0. 05). Conclusion Testosterone replacement therapy in patients with male late-onset hypogonadism and the Mild-to-moderate benige prostate hyperplasia is safe and effective.